Emergence of resistance to erythromycin and fluoroquinolones in thermotolerant Campylobacter strains isolated from feces 1987-1991.
During the period 1987 to 1991 a retrospective study was performed to determine the resistance of thermotolerant Campylobacter species isolated from feces to erythromycin and fluoroquinolones. Of the 672 strains studied, 614 (91.3%) were identified as Campylobacter jejuni and 58 (8.7%) as Campylobacter coli. During the study period the rate of resistance of Campylobacter jejuni to erythromycin remained relatively stable (0.9-3.5%), while resistance of Campylobacter coli to erythromycin emerged later (1989) with much higher rates (14.8-33%). Overall, 11.8% and 10.7% of Campylobacter jejuni strains isolated after 1987 were resistant to nalidixic acid and ciprofloxacin respectively, resistance increasing from 2.3% in 1988 to 32% in 1991. In 1991 the first strains of Campylobacter coli with resistance to these fluoroquinolones were detected (rates 29% and 26% respectively). Of the strains resistant to nalidixic acid, only 10.9% were susceptible to ciprofloxacin.
Reina
J
J
Clinical Microbiology Service, Hospital Son Dureta, Palma de Mallorca, Spain.
Borrell
N
N
Serra
A
A
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002167:Campylobacter / Q000187:drug effects*; D002169:Campylobacter Infections / Q000188:drug therapy*; D017000:Campylobacter coli / Q000187:drug effects / Q000302:isolation & purification; D016123:Campylobacter jejuni / Q000187:drug effects / Q000302:isolation & purification; D002648:Child; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000627:therapeutic use*; D005243:Feces / Q000382:microbiology*; D024841:Fluoroquinolones; D006358:Hot Temperature; D006801:Humans; D012189:Retrospective Studies
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D004917:Erythromycin